Marker Therapeutics: MT-601 shows durable CR in lymphoma patient 9 months post-CAR T failure; 3/3 objective responses

Marker Therapeutics, Inc.

First APOLLO participant with DLBCL who relapsed after CAR T remains in complete response 9 months after MT-601 treatment.
Second participant with transformed follicular NHL achieved CR at 8 weeks and remains in CR at 3 months.
Third participant with DLBCL (CAR T-ineligible) achieved partial response at 8 weeks with lesion shrinkage.
All three patients tolerated treatment well; no cytokine release syndrome or neurotoxicity reported.
Data presented at 11th Global Summit on Hematologic Malignancies on April 6, 2024 by City of Hope PI Dr. Shouse.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.